JAK2 and myelofibrosis: These results provide proof-of-principle that more chronic administration of a potent, orally delivered JAK2 inhibitor should have therapeutic effects on the polycythemia, and perhaps the myelofibrosis and hemostatic abnormalities, suffered by MPD patients carrying the JAK2 V617F mutation.